All In Biotech

Drug Trial Radar · NCT00135993

Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome

Last checked: Nov 20, 2026Latest source record: Sep 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 811 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

811

Actual

Start

May 2005

Primary completion

Nov 2006

Study completion Nov 2006

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Aug 26, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Subjects who meet the diagnosis of idiopathic restless legs syndrome (RLS) based on the 4 cardinal clinical features according to the International Restless Legs Syndrome Study Group (IRLSSG) are allowed to enroll in this trial. The primary objective of this trial is to demonstrate that rotigotine (SPM 936) is efficacious in subjects with idiopathic restless legs syndrome. Additional objectives are to investigate the safety and tolerability of rotigotine. Subjects will be randomized to receive either placebo, 1.125, 2.25, 4.5, or 6.75mg/day rotigotine in a 1:1:1:1:1 (active:placebo) fashion. Approximately 600 subjects will be enrolled in this trial, participating at approximately 60 sites. The maximum duration of the trial is approximately 8 months (consisting of a 4-week Titration Period, a 6-month Maintenance Period, a 7-day Taper Period, and a 30-day Safety Follow-Up Period).

Conditions

  • Restless Legs Syndrome

Interventions

  • RotigotineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. IRLS sum score and CGI Item 1 score severity of illnessTime frame: From Baseline at the end of the Maintenance Period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Schwarz

    RTP, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.